Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Caulfield, Australia Clinical Trials

A listing of Caulfield, Australia clinical trials actively recruiting patients volunteers.

RESULTS

Found (10) clinical trials

ANAVEX2-73 for Treatment of Early Alzheimer's Disease

This is a Phase 2b/3 48-week study to evaluate the effects of ANAVEX2-73 on cognition and function after 48 weeks of daily treatment. Additional outcome measures include refined measures of sleep, behavioral and psychological symptoms typically observed in AD, changes in daily functioning of participants and changes in caregiver burden, ...

Phase

1.89 miles

Learn More »

ANAVEX2-73 Study in Parkinson's Disease Dementia

This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group, three-arm, 14-week study in PD patients with dementia. The study includes a 2 week Screening / Baseline Observation Period and a 14-week Treatment Period (including a 2 week Titration Period), and a 2-week Safety Follow-Up Period

Phase

1.89 miles

Learn More »

High Intensity Interval Training in Fibrotic Interstitial Lung Disease

Interstitial lung disease (ILD) is a chronic lung condition characterized by scarring of lung tissue. This stiffening of the lungs impairs breathing and reduces the amount of oxygen being delivered throughout the body limiting the ability to perform daily and physical activity. Around two-thirds of people with ILD have fibrotic ...

Phase N/A

4.49 miles

Learn More »

Multi-center Open-label Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

Total study duration is variable depending on treatment and follow-up periods, including 21 days of screening, and treatment period until disease progression, unacceptable adverse reaction or other reason for discontinuation. End of treatment will be 30 days after last administration of investigational medicinal product, or approximately 14 months after first ...

Phase

4.49 miles

Learn More »

CLN-0046: Treatment of AMD Subjects With OTX-TKI

A multi-center, dose escalation, Phase 1, safety, tolerability and efficacy study to evaluate two dose groups of the OTX-TKI implant to treat subjects with a diagnosis of primary subfoveal neovascularization secondary to AMD.

Phase

5.97 miles

Learn More »

Nurse-led Antimicrobial Stewardship Intervention to Increase Antibiotic Appropriateness in Residential Aged Care Facilities

The study will explore the impact of a nurse-led bundled antimicrobial stewardship intervention on the appropriateness of antimicrobial use in residential aged care facilities (RACFs). The antimicrobial stewardship intervention will include the following components: Education Focused on antimicrobial stewardship and appropriate antimicrobial use Delivered face-to-face, via workbooks and fact sheets ...

Phase N/A

5.97 miles

Learn More »

Assessment of AMG 420 in Subjects With Relapsed and/or Refractory Multiple Myeloma

Cohort 1 will consist of 10 subjects dosed at 400 mcg/d. Cohort 2 will consist of 10 subjects dosed at 600 mcg/d. Cohort 3 (Phase 2) will consist of 100 subjects dosed at 400 mcg/d. If the 600 mcg/d dose is determined to be superior, Phase 2 subjects may potentially ...

Phase

6.49 miles

Learn More »

Vedolizumab in the Prophylaxis of Intestinal Acute Graft vs Host Disease in Participants Undergoing Allogeneic Hematopoietic Stem Cell (Allo-HSCT) Transplantation

The drug being tested in this study is called vedolizumab. Vedolizumab is being tested to treat people who are undergoing allo-HSCT transplantation. This study will look at the efficacy and safety of vedolizumab in the prophylaxis of intestinal aGvHD in participants undergoing allo-HSCT transplantation. The study will enroll approximately 558 ...

Phase

7.03 miles

Learn More »

A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk Children

This study is a pivotal Phase 2/3 randomized, double-blind, palivizumab-controlled study to evaluate the safety, pharmacokinetics (PK), anti-drug antibody (ADA) response, and descriptive efficacy for MEDI8897 in high-risk infants eligible to receive palivizumab when entering their first or second RSV season (Season 1 or Season 2, respectively). Approximately 1,500 palivizumab-eligible ...

Phase

8.02 miles

Learn More »

Study of TG-1801 in Subjects With B-Cell Lymphoma

This is an open-label, multi-center, accelerated titration design study. Planned enrollment includes 1 subject at low dose levels. Subjects will receive weekly infusions of TG-1801 in a 4 week-cycles.

Phase

9.42 miles

Learn More »